Formulation Development of a Transdermal Drug for Schizophrenia
First written in FY2017. 4 of 8 entries say "Advanced", first in FY2018. Latest entry: FY2020.
No other company in this theme has enough history to compare yet.
- FY2020AdvancedAnnual report
「In pharmaceuticals, an atypical antipsychotic received approval from the regulatory authorities in June 2019, and commercial-scale production began. Sales in the Japanese market were launched by Dainippon Sumitomo Pharma Co., Ltd. in September.」
For the transdermal tape formulation Lonasen® Tape, approval was obtained, commercial production began and domestic sales were launched. - FY2020-Q3RestatedAnnual report
「In addition, Lonasen® Tape, an atypical antipsychotic jointly developed with Dainippon Sumitomo Pharma Co., Ltd., performed well.」
The company stated that Lonasen® Tape, for which domestic sales approval had been obtained, was performing well following its joint development. - FY2020-Q2AdvancedAnnual report
「In addition, domestic sales of the atypical antipsychotic Lonasen® Tape 20mg, 30mg and 40mg, which had been jointly developed with Dainippon Sumitomo Pharma Co., Ltd., were approved.」
The jointly developed transdermal schizophrenia treatment progressed to the stage of obtaining approval for domestic sales. - FY2019AdvancedAnnual report
「In addition, an application was submitted to the regulatory authorities for the transdermal schizophrenia treatment based on the results of a domestic Phase 3 clinical trial.」
The application for the transdermal schizophrenia treatment was completed with the regulatory authorities based on the results of the domestic Phase 3 clinical trial. - FY2019-Q2RestatedAnnual report
「In collaboration with customers, development progressed on a transdermal tape formulation of an atypical antipsychotic indicated for the treatment of schizophrenia.」
The company stated that development of the transdermal tape formulation progressed through collaboration with customers, but did not indicate a new stage such as completion of clinical trials. - FY2019-Q1RestatedAnnual report
「We are developing transdermal tape formulations in collaboration with customers.」
Development of transdermal tape formulations in collaboration with customers is continuing. - FY2018AdvancedAnnual report
「In pharmaceuticals, favorable results were obtained in a domestic Phase 3 clinical trial of a transdermal schizophrenia treatment. In addition, we are advancing the development of next-generation transdermal formulation technologies applicable to a wide range of drugs.」
The company reported favorable results from a domestic Phase 3 clinical trial of its transdermal schizophrenia treatment and said that development of next-generation formulations is continuing. - FY2017First statedAnnual report
「In pharmaceuticals, progress was made in developing the world's first transdermal formulation for treating schizophrenia. In addition, we are advancing the development of next-generation transdermal formulation technologies applicable to a wide range of drugs.」
The company reported progress in developing the world's first transdermal formulation for treating schizophrenia, as well as the development of next-generation transdermal formulation technologies.